News

How to Use PT-141: It's As-Needed, Not Daily

Creator: Nadia Okonjo, Health Writer
Published: 2026-09-11

PT-141 is taken before anticipated activity rather than on a daily schedule. Here is what the approved label sets out, what a compounded vial changes, and what the prescriber decides.

Nadia Okonjo, Health Writer September 11, 2026 6 min read

A woman sits on the edge of a low bed in a bare, sunlit bedroom, hands resting in her lap

The short version

PT-141 is used as needed, not daily. The approved brand's label sets one 1.75 mg injection under the skin at least 45 minutes before anticipated activity, no more than one dose in 24 hours, and no more than eight a month.
Nausea is the effect that shapes real-world use: 40% in the phase 3 trials, worst the first time (21% after dose one, about 3% after later doses), starting within an hour and lasting about two hours.
Taking an anti-nausea tablet first does not help. In a study of 228 healthy women, 8 mg of ondansetron 30 minutes beforehand did not change the nausea rate, and the label advises against it.
Each dose raises blood pressure by about 6 mmHg systolic, peaking two to four hours later and settling within 12 hours — which is why the label rules the drug out for uncontrolled high blood pressure or known heart disease.
The brand autoinjector holds one fixed dose; a compounded vial's concentration is set by the prescription, so the pharmacy label is the only place the real number lives. It is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
Store it at or below 25°C and out of the light. A stability study published August 20, 2026 found bremelanotide degrades under heat, light and oxidation, and identified eight breakdown products.

The short answer to how to use PT-141 is that it is not a daily medicine. It is a small injection under the skin, taken when you expect to be sexually active — not every morning, not on a schedule.

The approved brand version, an autoinjector called Vyleesi, is labeled for one 1.75 mg dose in the belly or thigh, at least 45 minutes ahead, with no more than one dose in 24 hours and no more than eight a month. Those are label facts — the closest thing to a public instruction manual this molecule has.

They are not your instructions. If you are prescribed a compounded version, the amount, the timing and the spacing come from the provider who wrote the prescription and from the pharmacy label on the vial.

How to use PT-141 in practice

Here is the shape of it as the current prescribing label — revised March 2024 — describes it.

The question	What the approved brand's label says
When	At least 45 minutes before anticipated sexual activity
Where	Under the skin of the abdomen or the thigh
How close together	Never more than one dose in 24 hours
How often in a month	More than eight doses a month is not recommended
Before injecting	The liquid should look clear — not cloudy, nothing floating in it
If nothing changes	Treatment stops after eight weeks if symptoms have not improved

The label is candid about the rest: the duration of effect after a dose is unknown and the best window has not been fully worked out, so people settle on their own timing within those limits. Forty-five minutes is a floor, not a promise.

One practical detail from the same document: belly or thigh made no meaningful difference to how much drug reached the bloodstream. Site choice is comfort, not strength.

The brand pen and a compounded vial are not the same object

The autoinjector is one fixed dose sealed inside a device — 1.75 mg in 0.3 mL, single use, nothing to measure. A compounded vial is a different object: liquid at whatever concentration the pharmacy prepared, drawn up with a syringe.

So the number on a syringe barrel means nothing by itself. Milligrams live on the pharmacy label, and the conversion depends on that vial. For the numbers themselves — what the trials used, what the label uses — the PT-141 dosage page lays them out.

The other difference is regulatory. PT-141 through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded medicines are not reviewed by the FDA for safety, effectiveness or quality. That status is one input rather than the whole decision — a licensed provider may still prescribe a compounded formulation when they judge it appropriate, and that judgment sits between you and your doctor.

Nausea is what most changes how people use it

Roughly 2 in 5 people in the phase 3 trials felt sick after a dose: 40%, against 1% on placebo. That sounds worse than the lived version usually is, for two reasons.

It is mostly a first-time thing — about 1 in 5 after the very first dose, 21%, falling to around 3% after later ones. And it is short, typically starting within an hour and lasting about two hours.

One thing that does not help, which catches people out: taking an anti-nausea tablet first. In a study of 228 healthy women, half took 8 mg of ondansetron half an hour beforehand and half took a dummy tablet, and the nausea rate did not move. The label advises against it.

Blood pressure is the other reason spacing matters. Each dose nudges it up a little — about 6 mmHg systolic at its peak, two to four hours after the injection, back to normal usually within 12 hours. Small, in someone healthy. Not small if your blood pressure is not already controlled, which is why the label rules the drug out entirely for uncontrolled high blood pressure or known heart disease, and why doses are kept a day apart.

Flushing, headache and a tender injection site fill out the common list; the PT-141 side effects page has the fuller picture.

What the prescriber is actually deciding

Not the dose alone. First, whether this molecule fits the problem.

The evidence behind the approved product is narrow. Two phase 3 trials called RECONNECT randomized 1,267 premenopausal women whose low sexual desire distressed them, and the improvement over placebo was real but modest (Kingsberg et al., Obstetrics & Gynecology, 2019). The brand label states it is not indicated for postmenopausal women or for men, and not for enhancing performance. A 2026 review counted just nine completed drug trials for low desire in women, ever, with bremelanotide one of the two most studied (Ashour, Frontiers in Medicine, 2026). It is a thin field, and honest prescribing says so out loud.

So a provider weighs your heart history and blood pressure, whether pregnancy is possible, and your other medicines — the label notes that bremelanotide slows the stomach's emptying, which can change how tablets are absorbed, and singles out oral naltrexone to avoid alongside it. Then the harder question: whether something else entirely is driving low desire. A licensed provider reviews every request, and not everyone qualifies.

Sometimes the more useful conversation is a different molecule. Kisspeptin is the other compound here studied on the brain-signaling side rather than the blood-flow side, on a much smaller evidence base — the alternative a provider might raise when the picture looks more hormonal than motivational.

Storing it, and why the light matters

The storage line on the label is three short instructions: at or below 25°C (77°F), do not freeze, protect from light. That last one is not decoration.

As of September 6, 2026, the day this article was written, the newest published work on the molecule itself was a stability study from a pharmaceutical analysis group in India, out on August 20, 2026, which deliberately stressed bremelanotide with acid, alkali, heat, light and oxygen to see what breaks it (Yuvaraaj and Sharma, Analytical Methods, 2026). It proved especially vulnerable to oxidation and degraded under heat and light too; the authors identified eight breakdown products. That is a laboratory paper about the drug substance, not a study in people — but it is why the storage line on the carton reads the way it does.

How to store peptides covers the practical version, including what a warm car does to a vial.

The vials sold without a prescription

Search this compound and you will find it for sale in a few clicks, in vials labeled for laboratory use, not as medicine.

On August 24, 2026 the FDA sent warning letters to several online peptide sellers, naming PT-141 among the products at issue, and said the labeling on those vials did not change what the products were: the way the sites described and sold them showed they were meant for human use, which made them unapproved drugs (FDA warning letter to Peak Performance Peptides).

That is not a statement about the molecule. It is a statement about who is accountable for what is in the bottle — and about the fact that nobody at those sites is checking your blood pressure before you inject something that raises it. Are peptides legal unpacks the legal side.

The eight-week checkpoint

The approved label carries a stopping rule most people never hear about: if symptoms have not improved after eight weeks, stop.

As a question rather than a deadline, it is a good one for a follow-up. What are we watching, and when do we decide whether this is worth continuing? That belongs with the person who prescribed it.

Common questions

Is PT-141 taken daily or only when needed?

Only when needed. The approved brand's label describes a single injection taken at least 45 minutes before anticipated sexual activity, with no more than one dose in any 24 hours and no more than eight doses in a month. It is not a daily tablet and there is no build-up phase. A compounded prescription follows whatever schedule the prescribing provider sets.

How long before sex is PT-141 taken?

The label uses at least 45 minutes as the minimum. It also says openly that the duration of effect after a dose is unknown and the ideal window has not been fully characterized, so people are expected to find their own timing within the label's limits, based on how the effect and any nausea land for them. The prescriber sets that window.

Is PT-141 FDA-approved?

Not in the form offered here. There is an approved bremelanotide product, Vyleesi, cleared for one narrow use in premenopausal women, and that clearance does not extend to a compounded preparation, which is not FDA-approved. Compounded medicines are not reviewed by the FDA for safety, effectiveness or quality. A licensed provider may still prescribe one when they judge it appropriate.

Where is PT-141 injected?

Under the skin of the abdomen or the thigh, according to the label. The pharmacology section of that same document reports no meaningful difference in how much drug reached the bloodstream between the two sites, so the choice is about comfort and rotating the spot rather than about getting more or less effect from a dose.

Why does nausea happen, and does an anti-nausea tablet help?

Nausea was reported by 40% of people in the phase 3 trials, most often after the very first dose — 21% then, about 3% after later ones — starting within an hour and lasting roughly two hours. Taking ondansetron beforehand did not reduce it in a study of 228 healthy women, and the label advises against that approach.

What happens if it does not seem to work?

The approved label sets an eight-week checkpoint: if symptoms have not improved by then, treatment is stopped. For a compounded prescription that decision belongs to the provider who wrote it, alongside a look at tolerability, blood pressure and whether something else is driving low desire. It is a follow-up conversation, not a solo judgment.